Statistics

Total Visits

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial11

Select a period of time:

Number of views in the range

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial9

Views

Views
November 20232
December 20230
January 20241
February 20240
March 20242
April 20241
May 20243
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States9
 

Top cities views

Views
Ashburn2
Boardman1
Chicago1